Back to search results

Continuous Glucose Monitoring for Adolescents with Obesity

This study is looking at whether using a Continuous Glucose Monitor (CGM) can help teenagers with obesity and pre-diabetes (blood sugar levels higher than normal, but not yet diabetes) make healthier food choices. You would be between 13 and 17 years old and have a high Body Mass Index (BMI). Some participants will use an unblinded CGM device, which means they can see their blood sugar levels in real-time. The study aims to see if this awareness changes eating habits and blood sugar profiles. Researchers will measure your total calorie intake and the amount of sugar you eat at the beginning and after three months to see if the intervention is successful. The current recruitment status is unclear, and the study plans to enroll 100 participants.

Study design
This is an interventional study comparing two groups: one using a CGM device and one not. It is a feasibility and signal-of-efficacy trial, with 100 participants planned.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your total caloric intake and total grams of carbohydrates from sugar will be measured at the beginning and after 3 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07714759

A Study Comparing Continuous Glucose Monitoring Augmented Nutritional Counseling and Standard of Care Treatment Strategies in a Three-Month Nutrition Intervention

Not Yet Recruiting
NAAges 13–17InterventionalPrevention
University of Florida
~100 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:Use of an unblinded CGM device

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total caloric intake
Measured over Baseline; 3 Months
+1 more outcome measured

Conditions

Obesity & Overweight
Obese Adolescents
Metabolic Abnormalities

Explore related trials

ObesityOverweightPrediabetesHemoglobin A1C Measurement

Where it's being run

1 sites across 1 states
Florida1

Who to contact

Angelina Bernier, MD
[email protected]
508-558-0475
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Children aged 13-17 years.
BMI ≥ 95 percentile
BMI \>85th and BMI \< 95th percentile for age and sex (CDC growth charts) if the risk factors below are present: Family history of type 2 diabetes in first or second degree relative:
Race/ethnicity Native American, African American, Latino, Asian American, Pacific Islander
Signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight)
Maternal history of diabetes or gestational diabetes mellitus (GDM) during the child's gestation
Receiving care through HCN for pediatric or family medicine clinics.
No structured nutritional intervention in the past 3 months.
Parent/guardian able to provide informed consent and child able to assent.
Family has access to a smartphone or is willing to use a study-provided device for CGM viewing and communication.
Willingness to comply with study visits, CGM wear, and laboratory testing.

Exclusion

Diabetes by history or HbA1c ≥ 6.5 % in the medical record or at screening.
Unable or unwilling to provide consent or participate fully in study activities.
Conditions predisposing to diabetes or altering normal pubertal development.
Current or planned use of medications affecting glucose dynamics, including:
Known syndromic or monogenic obesity.
Blood disorders that impact HbA1c interpretation (e.g., anemia, and hemoglobin variants).
Major systemic organ disease (renal, hepatic, or cardiac).
History or planned bariatric surgery.
Current pregnancy or plans for pregnancy during the study.
Use or planned use of GnRH agonists, estrogen, or testosterone.
Non-English- or non-Spanish-speaking individuals, as validated questionnaires are available only in these languages.

What this trial measures

  • Total caloric intakeBaseline; 3 Months

    Total caloric intake as assessed from a validated 24-hour Dietary Recall

  • Total grams of carbohydrates from sugarBaseline; 3 Months

    Total grams of carbohydrates from sugar in food as assessed from a validated 24-hour Dietary Recall